Renin angiotensin system gene polymorphisms modify angiotensin-converting enzyme inhibitors' effect on cognitive function: The health, aging and body composition study

Journal of the American Geriatrics Society

Volumn 58, Issue 6, 2010, Pages 1035-1042

  Hajjar, Ihab ^a   Kritchevsky, Stephen ^b   Newman, Anne B ^c   Li, Rongling ^d   Yaffe, Kristine ^e   Simonsick, Eleanor M ^f   Lipsitz, Lewis A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensinogen gene; Cognitive function; Hypertension

Indexed keywords

ADENINE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GUANINE; HORMONE; METHIONINE; RENIN; THREONINE;

AFRICAN AMERICAN; AGED; AGING; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BRAIN FUNCTION; BRAIN PROTECTION; CAUCASIAN; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; FEMALE; GENE DELETION; GENE INSERTION; GENE INTERACTION; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANALYSIS OF VARIANCE; COGNITION DISORDERS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; NEUROPSYCHOLOGICAL TEST; RISK FACTOR;

AGED; AGING; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; BODY COMPOSITION; COGNITION DISORDERS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DELETION; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 77953118951     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02860.x     Document Type: Article

References (31)

1. Basso N, Paglia N, Cini R et al. Effect of omapatrilat on the aging process of the normal rat. Cell Mol Biol (Noisy-le-grand) 2005 51 : 557 564.
2. Raghavendra V, Chopra K, Kulkarni SK. Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides 1998 32 : 417 421.
3. Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003 163 : 1069 1075. (Pubitemid 36548935)
4. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. Lancet Neurol 2008 7 : 683 689.
5. Hajjar IM, Keown M, Lewis P et al. Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: An observational study. Am J Alzheimers Dis Other Demen 2008 23 : 77 83.
6. Kazama K, Anrather J, Zhou P et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004 95 : 1019 1026.
7. Rigat B, Hubert C, Corvol P et al. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992 20 : 1433.
8. Jeunemaitre X, Soubrier F, Kotelevtsev YV et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992 71 : 169 180.
9. Yanai K, Saito T, Hirota K et al. Molecular variation of the human angiotensinogen core promoter element located between the TATA box and transcription initiation site affects its transcriptional activity. J Biol Chem 1997 272 : 30558 30562.
10. Inoue I, Nakajima T, Williams CS et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997 99 : 1786 1797.
11. Schelleman H, Klungel OH, Witteman JC et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet 2007 15 : 478 484.
12. Royall DR, Palmer R, Chiodo LK et al. Executive control mediates memory's association with change in instrumental activities of daily living: The Freedom House Study. J Am Geriatr Soc 2005 53 : 11 17.
13. Swan GE, Carmelli D. Evidence for genetic mediation of executive control: A study of aging male twins. J Gerontol B Psychol Sci Soc Sci 2002 57B : P133 P143.
14. Pugh KG, Kiely DK, Milberg WP et al. Selective impairment of frontal-executive cognitive function in African Americans with cardiovascular risk factors. J Am Geriatr Soc 2003 51 : 1439 1444.
15. Royall DR, Cordes JA, Polk M. CLOX: An executive clock drawing task. J Neurol Neurosurg Psychiatry 1998 64 : 588 594.
16. Wechsler D. WMS-R: Wechsler Memory Scale - Revised: Manual.
17. Weissman MM, Sholomskas D, Pottenger M et al. Assessing depressive symptoms in five psychiatric populations: A validation study. Am J Epidemiol 1977 106 : 203 214.
18. Reich D, Patterson N, Ramesh V et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet 2007 80 : 716 726.
19. Yasar S, Zhou J, Varadhan R et al. The use of angiotensin-converting enzyme inhibitors and diuretics is associated with a reduced incidence of impairment on cognition in elderly women. Clin Pharmacol Ther 2008 84 : 119 126.
20. Harrap SB, Tzourio C, Cambien F et al. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003 42 : 297 303.
21. Winkelmann BR, Russ AP, Nauck M et al. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999 137 (4 Pt 1) : 698 705.
22. Li R, Nicklas B, Pahor M et al. Polymorphisms of angiotensinogen and angiotensin-converting enzyme associated with lower extremity arterial disease in the Health, Aging and Body Composition study. J Hum Hypertens 2007 21 : 673 682.
23. Wright JT Jr., Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005 293 : 1595 1608.
24. Flack JM, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: A new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin 2000 16 : 66 79.
25. Rice GI, Jones AL, Grant PJ et al. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 2006 48 : 914 920.
26. Barnes JM, Barnes NM, Costall B et al. Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989 491 : 136 143.
27. Marketou ME, Zacharis EA, Koukouraki S et al. Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus. J Hum Hypertens 2008 22 : 191 196.
28. Bonini JS, Bevilaqua LR, Zinn CG et al. Angiotensin II disrupts inhibitory avoidance memory retrieval. Horm Behav 2006 50 : 308 313.
29. Hishimoto A, Shirakawa O, Nishiguchi N et al. Association between a functional polymorphism in the renin-angiotensin system and completed suicide. J Neural Transm 2006 113 : 1915 1920.
30. Taylor A, Ezquerra M, Bagri G et al. Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes. Am J Med Genet 2001 105 : 761 764.
31. Lenkei Z, Palkovits M, Corvol P et al. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: A functional neuroanatomical review. Front Neuroendocrinol 1997 18 : 383 439.